Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask.

[1]  J. L. Rau,et al.  The importance of nonelectrostatic materials in holding chambers for delivery of hydrofluoroalkane albuterol. , 2006, Respiratory care.

[2]  Richard J Martin,et al.  Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. , 2005, The Journal of allergy and clinical immunology.

[3]  L. Hendeles,et al.  Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  A. Teper,et al.  Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. , 2005, American journal of respiratory and critical care medicine.

[5]  C. Crim,et al.  Fluticasone propionate HFA improves asthma control in pre-school age children with asthma , 2005 .

[6]  D. Postma,et al.  Side-effects of fluticasone in asthmatic children: no effects after dose reduction , 2004, European Respiratory Journal.

[7]  M. Newhouse,et al.  Safety of inhaled corticosteroids delivered by plastic and metal spacers , 2003, Archives of disease in childhood.

[8]  A. Tattersfield,et al.  Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects , 2003, Thorax.

[9]  S. Chesrown,et al.  Differences in Inhaled Fluticasone Bioavailability Between Holding Chambers in Children with Asthma , 2002, Pharmacotherapy.

[10]  S. Looney,et al.  Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. , 2002, Pediatrics.

[11]  T. Speroff,et al.  Management of chronic asthma. , 2001, Evidence report/technology assessment.

[12]  P. Seddon,et al.  Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone , 2001, Archives of disease in childhood.

[13]  H. Bisgaard,et al.  Lung deposition of inhaled drugs increases with age. , 2000, American journal of respiratory and critical care medicine.

[14]  H. Bisgaard,et al.  The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. , 2000, American journal of respiratory and critical care medicine.

[15]  Adnan Custovic,et al.  Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study , 2000, The Lancet.

[16]  L. Squassante,et al.  From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. , 2000, Respiratory medicine.

[17]  H. Möllmann,et al.  A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. , 2000, Journal of pharmaceutical and biomedical analysis.

[18]  B. Lipworth,et al.  Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate , 1999, Thorax.

[19]  H. Bisgaard,et al.  The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. , 1999, American journal of respiratory and critical care medicine.

[20]  B. Meibohm,et al.  A Pharmacokinetic/Pharmacodynamic Approach to Predict the Cumulative Cortisol Suppression of Inhaled Corticosteroids , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  W. Hop,et al.  Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. , 1999, The European respiratory journal.

[22]  L. Borgström,et al.  The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. , 1998, The European respiratory journal.

[23]  B. Meibohm,et al.  Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration , 1998, European Journal of Clinical Pharmacology.

[24]  G. Todd,et al.  Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate , 1996, The Lancet.

[25]  A. Tal,et al.  Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. , 1996, The Journal of pediatrics.

[26]  H. Bisgaard,et al.  A non-electrostatic spacer for aerosol delivery. , 1995, Archives of disease in childhood.

[27]  R. Ahrens,et al.  Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. , 1995, The Journal of allergy and clinical immunology.

[28]  S. Newman.  Spacer Devices for Metered Dose Inhalers , 2004, Clinical pharmacokinetics.

[29]  P. Daley-Yates,et al.  Bioavailability of Orally Administered Micronised Fluticasone Propionate , 2000, Clinical pharmacokinetics.